End-stage Renal Disease Clinical Trial
Official title:
Effect of an Exercise Rehabilitation Program on Symptom Burden and Quality of Life in Hemodialysis: A Randomized Controlled Study
NCT number | NCT02259413 |
Other study ID # | B2014:088 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2015 |
Est. completion date | June 8, 2023 |
Verified date | June 2023 |
Source | University of Manitoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether participation in a 26-week exercise rehabilitation program is effective at reducing symptom burden and improving quality of life in individuals receiving chronic hemodialysis.
Status | Completed |
Enrollment | 133 |
Est. completion date | June 8, 2023 |
Est. primary completion date | June 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - greater than 3 months after starting chronic hemodialysis - no planned change in hemodialysis modality or relocation outside of Winnipeg during study intervention period (26 weeks) - assessed to be safe and able to exercise by HD unit nephrologist - ability to communicate in English and provide informed written consent Exclusion Criteria: - acute coronary syndrome in past 3 months - unstable arrhythmia - shortness of breath at rest or with minimal activity (NYHA Class 4) - symptomatic hypoglycaemia (> 2x/week in week prior to enrolment) - currently participating in the Manitoba Renal Program clinical intradialytic cycling program - score of 0 on Dialysis Symptom Index when administered at time of consent |
Country | Name | City | State |
---|---|---|---|
Canada | Health Sciences Centre | Winnipeg | Manitoba |
Canada | Seven Oaks General Hospital | Winnipeg | Manitoba |
Canada | St. Boniface Hospital | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
University of Manitoba | The Wellness Institute at Seven Oaks General Hospital |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in physical activity behaviour pattern | Measured in 2 ways:
Subjectively using the self-reported Godin-Shephard Leisure Time Physical Activity Questionnaire Objectively using multi-directional accelerometers (Actical Physical Activity Monitors TM) which will be worn for 7 days at each measurement time point 2. |
Measured at study baseline, 12, 26 and 52 weeks after study start | |
Other | Hospitalization rate | Measured by number of hospitalizations and length of stay for each hospitalization | Measured at study baseline, 12, 26 and 52 weeks after study start | |
Other | Mortality | Measured as the proportion of people who died during the first year on dialysis | Measured at 1 year after starting dialysis | |
Primary | Change in dialysis symptom burden at 12 weeks | Measured using change in the Dialysis Symptom Index | Measured at study baseline and 12 weeks after study start | |
Secondary | Change in dialysis symptom burden at 26 and 52 weeks | Measured using change in the Dialysis Symptom Index | Measured at study baseline, 26 and 52 weeks after study start | |
Secondary | Change in modified symptom burden | Measured using change in modified Dialysis Symptom Index | Measured at study baseline, 12, 26 and 52 weeks after study start | |
Secondary | Change in health-related quality of life | Measured by self-report using the EuroQol 5D-5L (EQ5D-5L) and EuroQol Visual Analogue Scale. | Measured at study baseline, 12, 26 and 52 weeks after study start | |
Secondary | Change in time for recovery post-dialysis | Measured in minutes with the question "Approximately how much time does it take to recover from a dialysis session" | Measured at study baseline, 12, 26 and 52 weeks after study start | |
Secondary | Change in endurance/exercise capacity | Measured using the Incremental Shuttle Walk Test | Measured at study baseline, 12, 26 and 52 weeks after study start | |
Secondary | Change in frailty status | Measured using the Modified Fried Criteria for frailty. | Measured at study baseline, 12, 26 and 52 weeks after study start | |
Secondary | Change in self-efficacy for exercise | Measured using the Self-Efficacy for Exercise Survey a 9 item self-reported assessment tool | Measured at study baseline, 12, 26 and 52 weeks after study start |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087213 -
Study of HemoCareā¢ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
Terminated |
NCT03661229 -
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
|
N/A | |
Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A |